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Abstract
Background: Mutations in BRCA1 and BRCA2 genes
are associated with family predisposition to breast
and ovarian cancer. Novel screening methods are
required for efficient and rapid detection of sequence
variants in cancer patients and their family members.
Methods: The screening for variants in the breast and
ovarian cancer susceptibility genes BRCA1 and
BRCA2 in Croatia was performed by a high-resolution
melting approach, which is based on differences in
melting curves caused by variations in nucleotide
sequence. This is the first screening in Croatia on eld-
erly healthy women with no family history of cancer.
BRCA1 screening was performed on 220 and BRCA2
screening on 115 samples.
Results: In a population well beyond the average age
of breast/ovarian cancer onset, 21 different sequence
variants in the BRCA1 gene (one novel:
c.5193q49_50delTA) and 36 variants in the BRCA2
gene (7 novel: c.459A)C, c.3318C)A, c.4412_
4414delGAA, c.4790C)A, c.6264T)C, c.9087G)A,
and c.9864A)G) were detected.
Conclusions: Nine BRCA1 and seven BRCA2 known
variants appeared with such high frequencies that
they could be declared as harmless in this population.
Eight BRCA1 high frequency variants, located further
from the promoter region, appear to be strongly cor-
related. Three novel variants that changed the amino
acid sequence of the BRCA2 protein (two missense
base substitutions, c.3318C)A and c.4790C)A, and
one codon deletion c.4412_4414delGAA), appearing
only once, were predicted to have no potential effect
on protein structure and function.
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Introduction
BRCA1 and BRCA2 genes, involved in DNA repair
processes, are the major breast and ovarian cancer
susceptibility genes (1, 2). Epidemiological data indi-
cate that 5%–10% of all breast and/or ovarian cancers
are associated with inherited mutations in BRCA
genes (3, 4). The penetrance of deleterious BRCA
mutations has been variably estimated; a recent com-
bined analysis of different reports (5) estimates that
average cumulative risks (by age 70 years) in BRCA1
mutation carriers are 65% for breast cancer and 39%
for ovarian cancer, whereas the corresponding risks
for BRCA2 are 45% and 11%, respectively.
Carriers of BRCA1 or BRCA2 mutations are also at
increased risk for other cancers: uterine, cervical, ear-
ly-onset prostate and pancreatic cancer in BRCA1, and
male breast, prostate, pancreatic, gallbladder, bile
duct, stomach cancers and melanoma in BRCA2
(6, 7).
Various BRCA mutations associated with breast/
ovarian cancer may significantly differ in distribution;
some were found to be unique to the family tested or
to a specific group, whereas others appeared across
different populations (8). Most reported disease-asso-
ciated alleles of BRCA1 and BRCA2 have been attrib-
uted to frameshifts, nonsense or missense mutations,
large rearrangements and splice alterations. They
usually lead to the truncation of BRCA1 or BRCA2
protein, or affect amino acids that are critical for its
structure or function. However, a large number of
sequence variants, in particular missense variations,
routinely encountered in clinical and research labo-
ratories, cannot be readily distinguished as either
disease-causing (deleterious) mutations or benign
polymorphisms (clinically not significant), and thus
are classified as variants of unknown clinical
significance.
To date, more than 3500 BRCA1 and BRCA2 vari-
ants have been reported in the Breast Cancer Infor-
mation Core (BIC) database (http://research.
nhgri.nih.gov/projects/bic/index.shtml). This database
comprises accumulated research data gained from
both diseased and healthy individuals (9); no distinc-
tion is made between them, except for classification
by clinical significance.
No data on BRCA variants in an affected or healthy
population of Croatia have been collected so far.
Therefore, a pilot project involving the screening of
healthy women with the intention to facilitate the
introduction of genetic testing into the national pro-
gram of early detection of breast and ovarian cancer
was undertaken. In the Croatian population of 4.5 mil-
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Figure 1 Melting profiles analyzed with HR-1 software.
(A) Melting curve (plot of fluorescence vs. temperature) of
several samples analyzed for exon 17 of the BRCA1 gene.
Three distinct groups of curves represent different geno-
types: wild type, c.5074q65G)A homozygous, and
c.5074q65G)A heterozygous. (B) Samples shown as a
derivative plot (–dF/dT vs. temperature), showing the same
three groups of samples. (C) Samples shown as difference
plot (fluorescence vs. temperature), compared to a known
wild type sequence.
lion, an average of 2200 new breast cancer and 400
ovarian cancer cases have been reported annually
over the last 10 years (with a moderate tendency of
increase), and 800 women die of breast cancer each
year (data from the Central Bureau of Statistics of
Republic of Croatia and Croatian National Institute of
Public Health, 2006). Subjects for the screening pilot
project were recruited among elderly women with no
personal or family history of cancer, in order to iden-
tify benign high frequency variants of BRCA1 and
BRCA2 in the Croatian population.
The screening was performed by a high-resolution
melting approach, which is based on differences in
melting curves caused by variations in nucleotide
sequence; detected variants were confirmed by direct
sequencing. The high-resolution melting approach is
a rapid method for screening and detection of nucleo-
tide variations.
Patients and methods
Initially, 115 healthy Croatian females, aged between 64 and
100 years (mean age 78"8; median 76 years) were selected
to be screened for BRCA1 (MIM113705) and BRCA2
(MIM600185) sequence variants. Subsequently, the analy-
sis of BRCA1 was extended to another group of 105 healthy
women (matched by age with the first group) for reasons
described below.
All subjects were healthy, not undergoing any therapy,
and with no family history of breast, ovarian, prostate, colon,
pancreatic, or any other cancer. They were recruited from
several locations in the Zagreb area (General Medical Prac-
tice Kalinovica, General Medical Practice Dobojska, Gyne-
cological Clinic Srednjaci and Nursing Home for the Elderly
Godan). Blood samples were taken from subjects after they
had signed an informed consent form and were collected
adhering to all necessary ethical and legal requirements; all
were stripped of identifiers and could not be traced back to
subjects. All patients gave their informed consent to perform
DNA analysis on their blood samples before the samples
were taken. The study was conducted according to the Dec-
laration of Helsinki principles and approved by the Ethical
Committee of Clinical Hospital Petrova, University School of
Medicine, Zagreb (No. 021-1/49-2006) and by the Ethical
Committee of Medical Center Zagreb-West based on Health
Care Law of Republic of Croatia (NN121/03/). The study was
also strongly supported by the Croatian League Against Can-
cer (http://www.hlpr.hr) and the Croatian Society of Human
Genetics (http://hdhg.mef.hr).
DNA was extracted from peripheral blood leukocytes, and
the entire coding sequence and exon-intron boundarieswere
amplified using polymerase chain reaction (PCR) resulting in
36 PCR products sized 150–437 bp for BRCA1 and 49 PCR
products 179–500 bp long for BRCA2 (10).
PCR was performed in 10 mL reaction mixture containing
50 ng template DNA, 0.2 mM dNTPs (Roche, Mannheim,
Germany), 0.4 U FastStart Taq DNA Polymerase (Roche),
1= fluorescent dye LCGreen Plus (Idaho Technology, Salt
Lake City, ID, USA), 2 mM MgCl2 (Idaho Technology) and
forward and reverse primers (0.5 mM each) for each gene
segment, in Roche LightCycler capillaries and amplified in
an adapted RapidCycler2 instrument (Idaho Technology).
PCRs were performed using appropriate sets of primers as
described previously (10) with slight modifications (primer
sequences are available by e-mail: levanat@irb.hr).
PCR conditions were optimized to temperatures between
498C and 688C for each segment. After 40 cycles of amplifi-
cation, PCR products underwent an additional 1 min at 988C
and then 5 min at 408C to promote heteroduplex formation.
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Table 1 BRCA1 sequence variants in 220 healthy Croatian women (novel variant in boldface).
Nucleotide change AA change Proportion of Allele Exon BIC accession Times Clinically
carriers, % frequency, % no. or reported important
reference in BIC (reference)
Missense variants (ns11)
c.3548A)G p.Lys1183Arg 49.09 27.50 11 1099 33 No
c.4837A)G p.Ser1613Gly 46.82 24.77 16 1140 36 No
c.3113A)G p.Glu1038Gly 46.36 24.55 11 1087 37 No
c.2612C)T p.Pro871Leu 43.18 22.05 11 1067 26 No
c.1067A)G p.Gln356Arg 11.36 5.68 11 2558 82 No/little (17)
c.3119G)A p.Ser1040Asn 4.09 2.05 11 1089 45 No/little (17)
c.4956G)A p.Met1652Ile 2.73 1.36 16 1143 39 No/little (17)
c.4535G)T p.Ser1512Ile 1.36 0.68 15 1136 53 No
c.2077G)A p.Asp693Asn 0.91 0.45 11 1045 16 No
c.4039A)G p.Arg1347Gly 0.91 0.45 11 1351 154 No/little (17)
c.2002C)T p.Leu668Phe 0.45 0.23 11 2313 25 Unknown
Synonymous variants (ns4)
c.4308T)C p.s 42.27 25.23 13 1128 35 No
c.2082C)T p.s 44.55 24.77 11 1047 14 No
c.2311T)C p.s 40.00 20.23 11 1055 25 No
c.1911T)C p.s 0.45 0.23 11 Judkins et al. (18) 0 No (18)
Intronic variants (ns6)
c.5074q65G)A 45.91 26.59 17 Song et al. (19) No (19)
c.442-34C)T 43.18 22.95 8 1424 9 No
c.5075-53C)T 0.91 0.45 18 10455 2 Unknown
c.5277q48_59dup12 0.91 0.45 20 1292 26 No (20)
c.301q7G)A 0.45 0.23 6 2238 12 Unknown
c.5193H49_50delTA 0.45 0.23 19 – 0
Each capillary was then transferred to the High-Resolution
Melter instrument (HR-1, Idaho Technology) for high-reso-
lution melting and curve analysis. Samples were melted at
0.28C/s ramp rate. Melting profiles were analyzed with HR-1
software using fluorescence normalization, temperature shift
and conversion to difference and derivative plots (Figure 1).
Fragments with melting patterns different from the wild type
were sequenced to determine the exact sequence alterations
(11, 12). Coding variants are described according to the
GenBank accession number U14680 for BRCA1 and GenBank
accession number NM_000059.3 for BRCA2 reference
sequences. Intronic variants are described according to
GenBank accession number NG_005905.1 for BRCA1 and
GenBank accession number NW_001838072.1 for BRCA2
genes. Nucleotide numbering is based on cDNA sequence
and nucleotide q1 corresponds to A of the ATG translation
initiation codon. The nomenclature used in this study follows
the Nomenclature for Description of Genetic Variations
approved by the Human Genome Variation Society.
Before sequencing, the chosen PCR products were purified
with ExoSAP-IT (USB, Cleveland, OH, USA) and then
sequenced in both directions using the Big Dye Terminator
1.1 Cycle Sequencing kit (Applied Biosystems, Foster City,
CA, USA). Sequencing analysis was performed on an auto-
matic sequencer ABI PRISM 310 Genetic Analyzer (Applied
Biosystems).
Associations among nine BRCA1 sequence variants with
highest minor allele frequency (all conformed to Hardy-
Weinberg equilibrium) were assessed by measuring pair-
wise linkage disequilibrium (LD) using r2 statistics. All
calculations were carried out using HaploView (13).
Online splice prediction tools NNSPLICE (http://
www.fruitfly.org/seq_tools/splice.html) (14), SpliceSiteFinder
(http://violin.genet.sickkids.on.ca/;ali/splicesitefinder.html),
and ESEfinder3.0 (http://rulai.cshl.edu/tools/ESE/) (15) were
used to examine potential impact on the splicing for the
newly found variants. We used increased threshold values
of 2.0 for SF2/ASF and 3.0 for SC35, SRp40, and SRp55
motives in order to reduce false-positive results (16).
Results
Detected variants of BRCA1 and their frequencies in
the enlarged group of 220 subjects are listed in Table
1. The results for BRCA2 in the initial group of 115
subjects are listed in Table 2. Novel variants are given
in boldface.
BRCA1
We detected 21 different sequence variants in the
BRCA1 gene: 11 variants were missense, four were
synonymous and six were intronic. Figure 2 shows
their distribution along the gene/protein and the pro-
portion of homozygous/heterozygous carriers.
One novel sequence variant was detected: the intro-
nic variant c.5193q49_50delTA. For this intronic var-
iant, it was predicted by both NNSPLICE and
SpliceSiteFinder that a deletion of two nucleotides
would not change the score probability for the rec-
ognition of either donor or acceptor site.
Screening for BRCA1 variants was performed in the
enlarged group, because the results for the initial 115
subjects were suggesting strong correlation between
several high frequency variants. In order to obtain a
statistically more reliable picture, an additional 105
women were screened.
In the enlarged population, only four additional low
frequency variants were detected (they are included
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Table 2 BRCA2 sequence variants in 115 healthy Croatian women (novel variants in boldface).
Nucleotide change AA change Proportion Allele Exon BIC accession Times Clinically
of carriers, % frequency, % no. or reference reported important
in BIC (reference)
Missense variants (ns13)
c.1114A)C p.Asn372His 35.65 19.13 10 1668 9 No
c.865A)C p.Asn289His 8.70 4.35 10 1129 13 No
c.2971A)G p.Asn991Asp 8.70 4.35 11 1903 6 No
c.5744T)C p.Met1915Thr 5.22 2.61 11 1108 7 Unknown
c.968C)A p.Ser326Arg 3.48 1.74 10 1222 105 No
c.3515C)T p.Ser1172Leu 2.61 1.30 11 1908 43 No (21)
c.7544C)T p.Thr2515Ile 2.61 1.30 15 1547 71 No
c.125A)G p.Tyr42Cys 0.87 0.43 3 1004 141 No (22)
c.3318C)A p.Ser1106Arg 0.87 0.43 11 – 0
c.4258G)T p.Asp1420Tyr 0.87 0.43 11 1274 191 No
c.4790C)A p.Ser1597Tyr 0.87 0.43 11 – 0
c.6100C)T p.Arg2034Cys 0.87 0.43 11 1324 97 Unknown
c.6935A)T p.Asp2312Val 0.87 0.43 12 5423 5 No (21)
Synonymous variants (ns14)
c.3396A)G p.s 46.09 23.91 11 1661 8 No
c.7242A)G p.s 43.48 23.04 14 1125 10 No
c.3807T)C p.s 33.04 19.57 11 1662 3 No
c.1365A)G p.s 8.70 4.35 10 1106 7 No
c.2229T)C p.s 7.83 3.91 11 13616 7 No
c.6264T)C p.s 1.74 0.87 11 – 0
c.198A)G p.s 0.87 0.43 3 Konstantopoulou No (23)
et al. (23)
c.459A)C p.s 0.87 0.43 5 – 0
c.1938C)T p.s 0.87 0.43 11 2907 2 No
c.3516G)A p.s 0.87 0.43 11 3501 4 No
c.4068G)A p.s 0.87 0.43 11 3525 3 Unknown
c.5199C)T p.s 0.87 0.43 11 1941 2 No
c.9087G)A p.s 0.87 0.43 23 – 0
c.9864A)G p.s 0.87 0.43 27 – 0
Intronic and non-coding variants (ns5)
c.7806-14C)T 73.04 46.52 17 1126 15 No
c.6841q80_83delTTAA 61.74 38.26 11 2022 1 Unknown
c.-26G)A 55.65 35.65 2 1666 12 No
c.425q67A)C 8.70 4.35 4 Seo et al. (24) No (24)
c.9257-16T)C 0.87 0.43 25 1123 6 Unknown
Truncating mutations (ns3)
c.5645C)A p.Ser1882X 0.87 0.43 11 1036 26 Yes
c.9976A)T p.Lys3326X 0.87 0.43 27 1179 293 No
c.10095delCins11 p.Ser3366AsnfsX4 0.87 0.43 27 1788 11 No
Deletions (ns1)
c.4412_4414delGAA p.Arg1471del 0.87 0.43 11 – 0
among the 21 variants in Table 1). Also, the previous
structure of the high frequency group (nine variants
with similar allele frequencies, 20%–30% each)
remained essentially unchanged (online supplemen-
tary Figure 1 illustrates the frequencies for the entire
set of subjects). Characterization of linkage disequilib-
rium among nine most frequent BRCA1 (Table 1)
sequence variants proved that eight out of nine of
them manifest higher association (r2 from 0.346 to
0.768), while sequence variant c.442-34C)T stays
clearly outside that cluster (Figure 3).
BRCA2
We found 36 different sequence variants in the BRCA2
gene: 13 of them were missense, 14 synonymous, five
intronic variants, three truncating mutations and one
deletion. Figure 4 shows their distribution along the
gene/protein and the proportion of homozygous/het-
erozygous carriers.
Seven novel sequence variants were detected: four
synonymous (c.459A)C, c.6264T)C, c.9087G)A,
and c.9864A)G), two missense (c.3318C)A and
c.4790C)A) and one deletion (c.4412_4414delGAA).
For the synonymous variant c.459A)C in exon 5 (N-
terminal), ESEfinder 3.0 predicted loss of one SRp40
motif and appearance of one SF2/ASF motif. For the
c.6264T)C in exon 11 (BRC repeats), it predicted loss
of one SF2/ASF motif and gain of one SC35 motif. The
other two novel synonymous variants, both missense
variants and the deletion, analyzed in silico, do not
cause changes in ESE splicing motifs. None of these
variants leads to the creation of potential cryptic
splice sites.
Variants of BRCA2 were also divided into two fre-
quency groups (online supplementary Figure 2), but
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Figure 2 Locations of 21 detected BRCA1 sequence variants in relation to BRCA1 protein with its domains.
Circles represent missense variants, squares synonymous, whereas non-coding variants are drawn only with gray lines denot-
ing their position relative to coded counterparts. Columns above the protein represent the proportion of heterozygous (black)
and homozygous (gray) carriers for each variant.
Figure 3 Pairwise linkage disequilibrium (LD) of nine
BRCA1 sequence variants with highest minor allele
frequency.
The location of each sequence variant along the BRCA1 gene
is relative to the real nucleotide position. The number in each
diamond indicates the intensity of LD (r2=10–2) between
respective pairs of sequence variants. The strength of LD is
represented by shades of gray (0 wwhitex-r2-1 wblackx).
with great variations within the high frequency group,
so the screening was not extended beyond the initial
set of 115 women. Three leading variants appeared
with far greater frequencies than in the BRCA1 case
and differed too much among themselves as well as
from the others for any large scale correlation.
Discussion
Distribution of variants across the protein domains
BRCA1 protein contains two highly conserved
regions; one is the RING finger domain and the other
BRCT domains (Figure 2). Mutations in the RING fin-
ger domain were detected in breast cancer patients
from Chile, Japan and India (25–27), and several large
studies in Italy and Germany (6, 28–37) showed poly-
morphisms and mutations in this region in patients
but also in the control population. However, consis-
tent with the conserved status of the region, we did
not detect any variants of the RING finger domain in
the healthy Croatian population. The only alteration
we found in the BRCT domains that could alter DNA
repair function was c.4956G)A, but it had already
been classified as a neutral polymorphism (38–40).
Most of the BRCA1 variants detected in the Croatian
population were in the DNA binding domain and
downstream. High incidence of missense variants
indicates this region is not as vital as the RING finger
or BRCT domains. These missense variants have pre-
viously been reported in both healthy individuals and
patients with similar frequencies, indicating that they
are not clinically significant (27, 30, 38–40).
Unlike BRCA1, BRCA2 conserved regions were not
so free of variants. The conserved BRC repeats region
(Figure 4) is essential for the BRCA2 protein function
in DNA repair and contains the ovarian cancer cluster
region (OCCR, bounded by nucleotides 3059–4075
and 6503–6629) that is associated with ovarian cancer
family history (41). Mutations in the BRC repeats are
common in Japanese, Indian, German, Greek and
Korean breast and ovarian cancer patients (26, 27, 36,
42–44). However, in this region we found 15 different
variants in the healthy Croatian population, although
most of them with low incidence (the exceptions were
two synonymous variants). In the other conserved
region of the BRCA2 gene, the C-terminal domain, we
detected only four variants. One of them was synon-
ymous, two non-coding, and one missense variant
(c.7544C)T), which had been previously reported to
have no effect on the BRCA2 protein function (45).
Remaining parts of the BRCA2 sequence are not as
conserved. Here, we detected most variants, includ-
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Figure 4 Locations of 36 detected BRCA2 sequence variants in relation to BRCA2 protein with its domains.
Circles represent missense variants, squares synonymous, triangle is a deletion and X denotes truncating mutations, whereas
non-coding variants are drawn only with gray lines denoting their position relative to coded counterparts. Columns above
the protein represent the proportion of heterozygous (black) and homozygous (gray) carriers for each variant.
ing five missense alterations, as well as two stop var-
iants leading to truncation of the C-terminus of the
protein.
Clinical significance of the variants
The elderly population in this screening was well
beyond the average age of onset of breast/ovarian
cancer; therefore, high frequency variants of BRCA1
and BRCA2 would be most unlikely to cause cancer
predisposition. Due to the sharp division between
high and low frequency groups, a conservative limit
of more than 30% carriers can be set for both genes,
leading to nine BRCA1 and seven BRCA2 variants that
can be declared as harmless in this population. All
these high frequency variants also regularly appear in
homozygous form, indicating them as harmless, since
homozygous mutations in BRCA1 are usually lethal
(46) and in BRCA2 lead to Fanconi anemia (47) (OMIM
605724).
Significance of the lower frequency variants cannot
be judged on the basis of our screening: 12 of them
appeared in 2%–11% of the subjects and the remain-
ing 29 were of the order of 1% or less. Their very low
appearance among these elderly subjects with no
family history of cancer does not support their pre-
disposing potential, or at least suggests limited pen-
etrance. Only one variant from our population,
c.5645C)A in BRCA2, has been classified as delete-
rious mutation (29). The German Consortium for
Hereditary Breast and Ovarian Cancer found this
mutation in two different families (33). We found it in
a single sample and in a heterozygous form (an 87-
year-old woman with no family history of breast or
ovarian tumors, and with no sporadic disease). We
cannot speculate any more on the significance of this
variant in tumor formation. Various factors play a role
in tumor formation and a mutation is only one of
them. A mutation in one of these genes does not
imply the person will develop a tumor; it only increas-
es the risk, which can be as high as 80% by the age
of 70 (8). Samples with a family history of cancer may
provide answers about penetrance and expressivity
of the complex cancer disease.
All our novel variants appear in one or two cases
each, so their significance cannot be judged by inci-
dence. For missense variants c.3318C)A and
c.4790C)A, tools, such as Align-GVGD (http://
agvgd.iarc.fr) (38), SIFT (http://blocks.fhcrc.org/sift/
SIFT.html) (48), and PolyPhen (http://coot.embl.de/
PolyPhen/) (49), have predicted that these amino acid
changes in BRCA2 protein are tolerated so they could
have no potential effects on protein function.
Although the 3D structure of complete BRCA2 is not
yet determined, arginine 1471 in BRCA2 protein is not
conserved among species (38), neither does it belong
to any functional domain (http://smart.embl-heidel-
berg.de) (50). Therefore, it is likely that deletion of
amino acid at that position also has no potential
harmful effects. The two synonymous variants
(c.459A)C and c.6264T)C) showed potential chang-
es in splicing motifs, which could disrupt the usual
splicing pattern. It has been previously reported that
changes in exon sequence can cause exon skipping
in BRCA1 and BRCA2 genes, although only for non-
sense or missense mutations (51, 52). It was shown
by Pettigrew et al. (53) that reported unclassified
sequence variants in BRCA2 were found to colocalize
to 55% of predicted ESEs, while previously reported
polymorphisms do not colocalize to the conserved
ESEs. This suggests that potential motifs can be indic-
ative if detected in unclassified variants, because they
are not present in benign polymorphisms.
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Application of high-resolution melting
Sensitivity and specificity of this method in scanning
for polymorphisms have been previously shown to be
95% and 99%, respectively (11). In this study, we con-
ducted sequencing of suspect forms, and all hetero-
zygous forms were identified without error. Difference
plot was the most informative in our study; different
sequence variants were most easily distinguishable in
this plot. All the variants were easily detected based
on curve shapes, and the same type variants always
grouped together (Figure 1); therefore, such variants
could be easily distinguished without the need for
sequencing. Samples with other sequence variants
regularly differed from all other curves, clearly distin-
guishing them as different. All of these curve patterns
were verified by sequencing. We tested the applica-
tion of this method in mutation detection, using 25
coded samples with known mutations and detected
them by high-resolution melting in all cases. All the
curves differed from wild type and from all other var-
iants (example in online supplementary Figure 3).
High-resolution melting is an effective method for
variant detection in BRCA1 and BRCA2 genes and can
be applied for rapid screening of samples in gene
testing (54, 55).
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